Kailera Therapeutics and its Chinese partner Hengrui Pharma have reported positive Phase 3 trial results for their oral obesity pill HRS-7535, marking a significant development in the rapidly expanding oral GLP-1 receptor agonist market. At the highest daily dose tested, the drug helped patients lose an average of 9.8% of their body weight over 44 weeks, positioning it as a potential competitor to Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide formulations.

The data, disclosed Tuesday, showed that HRS-7535 also meaningfully reduced blood sugar levels in a separate late-stage diabetes trial, underscoring the drug's dual potential in both obesity and type 2 diabetes — two of the largest and fastest-growing therapeutic markets globally. The oral format offers a key convenience advantage over injectable GLP-1 therapies, which have dominated the market but require frequent subcutaneous administration.

However, the trial results came with a notable safety signal that has drawn attention from analysts. At the highest dose, approximately 70% of recipients experienced nausea and 67% to 69% reported vomiting — rates that one analyst described as "alarming." These gastrointestinal side effects are a known class effect of GLP-1 receptor agonists, but the incidence rates observed with HRS-7535 exceed those reported for competing oral formulations. In a note to investors, analysts suggested that reducing nausea and vomiting rates to roughly 35% and 20% respectively would be necessary to achieve a competitive commercial profile.

Kailera is currently running an ongoing global Phase 2 trial that addresses this concern by starting with a lower dose and exploring a "nighttime" dosing cohort, which could potentially mitigate gastrointestinal tolerability issues by allowing patients to sleep through peak side-effect periods. The company and Hengrui have not yet completed the kind of broader global Phase 2 study in obesity that the U.S. Food and Drug Administration typically requires for approval, meaning the path to regulatory submission in Western markets remains lengthy.

The oral GLP-1 market is shaping up to be one of the most competitive battlegrounds in pharmaceutical history. Eli Lilly's orforglipron, branded as Foundayo, has already received FDA approval and demonstrated approximately 7.9% weight loss in its pivotal program. Novo Nordisk's oral semaglutide, marketed under the Wegovy brand in injectable form, is advancing its higher-dose oral formulation through late-stage trials. With the obesity drug market projected to exceed $100 billion by 2030, multiple oral products are expected to coexist, each capturing segments based on efficacy, tolerability, convenience, and pricing.

For pharmaceutical API suppliers and contract manufacturers, the proliferation of oral GLP-1 candidates represents a substantial and sustained demand signal. GLP-1 receptor agonists are peptide-based molecules that require complex synthesis processes, including solid-phase peptide synthesis and specialized purification steps. The manufacturing of oral formulations adds additional complexity, as the active ingredient must be combined with permeation enhancers and formulated into tablets or capsules that can survive the gastrointestinal environment while maintaining bioavailability.

Hengrui Pharma, one of China's largest pharmaceutical companies, has been steadily building its metabolic disease portfolio and global ambitions. The partnership with Kailera — a U.S.-based biotech focused on metabolic diseases — exemplifies the growing trend of Chinese-Western pharmaceutical collaborations that leverage Hengrui's manufacturing scale and clinical development capabilities in China alongside Kailera's regulatory and commercial expertise in Western markets. For API suppliers serving the global supply chain, this model creates demand across both Chinese and international manufacturing sites.

The competitive dynamics in oral GLP-1 development have significant implications for the broader pharmaceutical supply chain. As more late-stage candidates advance toward approval, API manufacturers must scale production capacity for peptide active ingredients, while finished dosage form manufacturers need to invest in specialized oral solid-dose capabilities. The high volume of patients expected to use these therapies — some analysts project hundreds of millions of potential users worldwide — means that manufacturing scale will be a critical differentiator.

For B2B pharmaceutical suppliers, the key takeaway from Kailera's Phase 3 data is that the oral GLP-1 market is not consolidating around a single winner. With multiple viable candidates now demonstrating clinically meaningful weight loss in late-stage trials, the demand for peptide API manufacturing, formulation development, and finished-dose production will continue to expand. Suppliers with expertise in peptide synthesis, oral formulation technologies, and scalable GMP manufacturing are well-positioned to benefit from this structural growth trend.

The coming 12 to 18 months will be critical for Kailera and Hengrui as they work to complete their global Phase 2 program and address the tolerability concerns raised by the Phase 3 data. Success in optimizing the dosing regimen could unlock a multi-billion-dollar commercial opportunity and further intensify demand across the GLP-1 manufacturing supply chain.